-34.6%
SNPS vs MRNA
+511.3%
-545.9%
-38.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.4% | -2.2% | -3.2% | -5.4% |
| 7D | -11.0% | +5.5% | -16.5% | -11.1% |
| 30D | -1.7% | +158.7% | -160.5% | -4.8% |
| 3M | -20.4% | +182.1% | -202.5% | -24.3% |
| 6M | -8.6% | +151.8% | -160.4% | -12.3% |
| YTD | -16.2% | +393.6% | -409.7% | -26.7% |
| 1Y | -34.6% | +499.5% | -534.0% | -46.9% |
| All | -34.6% | +511.3% | -545.9% | -46.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling